Identification of New Biomarkers and Potential Therapeutic Targets in Clinical Osteoporosis Using Omics Technologies
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Identification of Metabolomic Biomarkers
研究概览
简要总结
This study aims to discover novel biomarkers and therapeutic targets for osteoporosis through the use of advanced omics technologies, including proteomics and metabolomics. By analyzing bone and plasma samples from patients with osteoporosis, the research seeks to understand the underlying mechanisms of the disease and identify potential diagnostic and therapeutic biomarkers.
详细描述
Study Objectives:
- To investigate the proteomic profile of bone and plasma in clinical osteoporosis compared to patients with osteoarthritis.
- To study the metabolomic profile of serum in clinical osteoporosis compared to patients with osteoarthriti.
- To identify and validate potential biomarkers for osteoporosis diagnosis and treatment.
- To elucidate the pathophysiological mechanisms involved in osteoporosis.
Methodology:
Clinical Osteoporosis:
Patient Recruitment: 60 postmenopausal women will be divided into two groups: those with osteoporotic hip fractures and a control group with osteoarthritis undergoing total hip replacement.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Postmenopausal Female Patients with osteoporotic subcapital femoral neck fracture (Arm 1)
- •Postmenopausal Female Patients with hip osteoarthritis that will undergo Total Hip Replacement (Arm 2)
排除标准
- •Patients that have undergone before osteoporotic fractures
- •Patients with severe cardiovascular, pulmonary, autoimmune, or urinary system conditions
结局指标
主要结局
Identification of Metabolomic Biomarkers
时间窗: Up to 18 months
The number of small molecules identified through metabolomic analysis that differ significantly between osteoporosis and control groups.
Identification of Proteomic Biomarkers
时间窗: Up to 18 months.
The number of proteins identified through proteomic analysis that differ significantly between osteoporosis and control groups
次要结局
- Microarchitecture Assessment(Up to 18 months)
- Bone Density Assessment(Up to 18 months)
- Correlation of Omics Data with Clinical Markers(Up to 18 months)
- Identification of Disrupted Pathways(Up to 18 months)
研究者
EFSTATHIOS CHRONOPOULOS
Professor in Orthopedics at National and Kapodistrian University of Athens, Laboratory for Research of the Musculoskeletal System Director
National and Kapodistrian University of Athens